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The regulation of acetylation is central for the epigenetic control of lineage-specific gene 
expression and determines cell fate decisions. We provide evidence that the inhibition of 
histone deacetylases (HDACs) blocks the endothelial differentiation of adult progenitor cells. 
To define the mechanisms by which HDAC inhibition prevents endothelial differentiation, we 
determined the expression of homeobox transcription factors and demonstrated that 
 
HoxA9
 
 
expression is down-regulated by HDAC inhibitors. The causal involvement of 
 
HoxA9
 
 in the 
endothelial differentiation of adult progenitor cells is supported by the finding that 
 
HoxA9
 
 
overexpression partially rescued the endothelial differentiation blockade induced by HDAC 
inhibitors. Knockdown and overexpression studies revealed that 
 
HoxA9
 
 acts as a master 
switch to regulate the expression of prototypical endothelial-committed genes such as 
endothelial nitric oxide synthase, 
 
VEGF-R
 
2
 
, and VE-cadherin, and mediates the shear stress–
induced maturation of endothelial cells. Consistently, 
 
HoxA9
 
-deficient mice exhibited lower 
numbers of endothelial progenitor cells and showed an impaired postnatal 
neovascularization capacity after the induction of ischemia. Thus, 
 
HoxA9
 
 is regulated by 
HDACs and is critical for postnatal neovascularization.
 
Endothelial progenitor cells (EPCs) can origi-
nate from bone marrow–derived progenitor
cells, circulate with the blood on mobilization
from the bone marrow, and home to sites of
active vessel growth, a process termed “adult
vasculogenesis” (1, 2). The recruitment of
EPCs is involved in tumor vascularization
(3, 4) and contributes to ischemia-triggered
neovascularization (5–8). Although the exact
characterization of the EPCs is not entirely
clear, various studies suggest that EPC de-
velop from common endothelial and hemato-
poietic precursor cells, so-called adult heman-
gioblasts (1, 2, 9). The molecular mechanisms
directing endothelial differentiation from stem
or progenitor cells, however, are incompletely
understood.
As a vehicle for modulating gene expression,
chromatin structure remodeling plays a central
role in normal development, the physiological
differentiation of cells, and both embryonic
and adult stem cell functions (10, 11). Indeed,
the acetylation of histones is part of the com-
plex epigenetic regulatory process determining
lineage-specific gene expression and cell fate
decisions by altering the local structure of
chromatin (12). Previous reports suggest that
the global deacetylation of histones is necessary
for in vitro differentiation of embryonic stem
(ES) cells (13) and oligodendrocyte lineage
progression (14). The interplay between his-
tone acetyltransferases and histone deacetylases
(HDACs) is a key regulator in the dynamics of
chromatin structure and function. The family
of HDACs comprises at least 17 genes that are
classified into three groups. Class I HDACs
(
 
HDAC1
 
, HDAC2, HDAC3, and HDAC8)
and class II HDACs (HDAC4, HDAC5,
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HDAC6, HDAC7, HDAC9, and HDAC10) can deacety-
late histone tails and target other cellular proteins (15). Class
III HDACs (Sirtuins) were identified on the basis of their
similarity with sir2, a yeast transcription repressor requiring
NAD
 
 
 
 as a cofactor (16). Importantly, the inhibition of
HDAC was shown not only to block postnatal vessel growth
in an animal model of tumor vascularization (17), but also to
down-regulate the endothelial nitric oxide synthase (eNOS;
reference 18). Thus, we hypothesized that HDAC activity
may be required for endothelial differentiation of progenitor
cells. Because HDAC inhibitors blocked endothelial differ-
entiation, we further explored the down-stream mecha-
nisms, thereby focusing on the acetylation-dependent regu-
lation of homeobox genes (Hox’s).
Hox’s encode transcriptional regulatory proteins, which
are characterized by a common 60-amino acid DNA-bind-
ing motif and regulate differentiation during embryonic de-
velopment and tissue morphogenesis (19). Members of the
Hox family of homeodomain transcription factors play im-
portant roles in the embryonic development of the cardio-
vascular system and also regulate angiogenesis in the adult
organism (for review see reference 20). Several Hox tran-
scription factors (e.g., HoxD3, HoxC6, and HoxC8) modu-
late the expression of integrins, adhesion molecules, and ex-
tracellular matrix proteins in mature endothelial cells (21,
22), whereas HoxB5 appears to be involved in the in vitro
differentiation of embryonic precursor cells toward endothe-
lial lineage (23). 
 
HoxA9
 
, which is important for myeloid,
erythroid, and lymphoid hematopoiesis (24, 25) and stem
cell expansion (26), is also particularly essential for the mi-
gration and tube-forming capacity of mature endothelial
cells (27) and, thus, could serve as a switch toward endothe-
lial commitment during progenitor cell maturation.
Our present data demonstrate that HDAC inhibition ab-
rogates the endothelial differentiation of progenitor cells and
reduces the expression of the homeobox transcription factor
 
HoxA9
 
. Knockdown and overexpression studies revealed
that 
 
HoxA9
 
 is a critical regulator of postnatal neovasculariza-
tion and acts as a master switch to direct expression of the
endothelial-committed genes.
 
RESULTS
HDAC inhibitors abrogate endothelial differentiation 
of progenitor cells
 
To test the involvement of HDAC activity in endothelial
lineage progression, we investigated the effects of HDAC
inhibitors on EPCs derived from peripheral blood mononu-
clear cells (MNCs; references 28, 29). Adherent DiI-Ac-
LDL–labeled EPCs express the endothelial marker proteins
von Willebrand factor (vWF), CD105, and VE-cadherin
and bind lectin (Fig. S1, available at http://www.jem.org/
cgi/content/full/jem.20042097/DC1; references 28, 29).
Four structurally unrelated HDAC inhibitors—butyrate
(BuA), MS-275, Trichostatin A (TSA), and valproate—
inhibited the generation of EPCs (Fig. 1, a–c; and Fig. S2).
Moreover, HDAC inhibitors selectively reduced the ex-
pression of 
 
VEGF-R
 
2
 
 during the culture of MNCs in endo-
thelial differentiation medium, whereas the proportion of
CD45
 
 
 
 cells and CD14
 
 
 
 monocytes remained unchanged
(Fig. 1 d). Similarly, HDAC inhibitors also prevented the
endothelial differentiation of bone marrow–derived human
CD34
 
 
 
 hematopoietic progenitor or murine Sca-1
 
 
 
/lin
 
 
Figure 1. HDAC inhibitors abrogate the ex vivo endothelial matura-
tion of circulating mononuclear precursor cells. (a–c) Dose-dependent 
effect of MS-275 (a), TSA (b), and BuA (c) on the number of EPCs after 
72 h (n   3–7, mean   SD). (c) The effect of 2 mM BuA on EPC 
formation under these conditions in the presence or absence of 100  M 
of the pan-caspase inhibitor zVAD (n   4). (d) Relative changes in 
VEGF-R2
 , CD14 , and CD45  cells in peripheral blood–derived total 
MNCs after incubation in endothelial growth factor medium for 72 h with 
or without 2 mM BuA (*, P   0.05 vs. CD14 , P   0.005 vs. CD45 ; n   6, 
mean   SEM). (e and f) Confocal microscopy of human bone marrow 
CD34 –derived (e) or murine bone marrow Sca-1 /lin –derived (f) EPCs 
stained with DiI-Ac-LDL (red fluorescence) and vWF (green fluorescence), 
and nuclear TO-PRO-3 staining (blue fluorescence) after exposure toward 
endothelial differentiation conditions for 72 h in the presence or absence 
of 2 mM BuA. Representative images out of three to six experiments are 
shown. (g) Flow cytometric analysis of the expression of integrin subunits 
 4 (CD49d),  5 (CD49e), or  1 integrin (CD29, fibronectin receptor) in 
peripheral blood MNCs after exposure toward endothelial differentiation 
conditions for 72 h with or without 2 mM BuA or 3  M MS-275 (n   3–4). 
(h) Vascular outgrowth from embryonic allantois explants stained with 
CD31 antibody. 
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cells, both of which were exposed to the same endothelial
differentiation conditions (Fig. 1, e and f ).  Control experi-
ments confirmed that the reduction in numbers of EPCs
was not related to an antiadhesive or proapoptotic effect of
the HDAC inhibitors, because integrin expression (Fig. 1 g)
and EPC adhesion and apoptosis rates (Figs. S3 and S4, re-
spectively) were not affected. In addition, caspase inhibitor
treatment did not reverse the effect of HDAC inhibitors
(Fig. 1 c). In summary, these data suggest that HDAC in-
hibitors interfere with the ex vivo endothelial lineage pro-
gression of circulating peripheral blood- or bone marrow–
derived progenitor cells.
To investigate the effect of HDAC inhibitors in a physi-
ological model of vasculogenesis and angiogenesis, we per-
formed an ex vivo analysis of new vessel growth in the allan-
tois assay. The HDAC inhibitors MS-275 (3 
 
 
 
M) and BuA
(2 mM) profoundly blocked the formation of a vascular net-
work from embryonic progenitor cells (Fig. 1 h and not de-
picted), indicating that HDAC activity is required for ex
vivo vessel growth.
 
HDAC inhibition down-regulates 
 
HoxA9
 
 expression 
and EPC formation
 
Because homeobox transcription factors play important roles
in the embryonic development of the cardiovascular system
and in neovascularization in the adult organism (20, 27), we
postulated that the expression of Hox proteins might be al-
tered by HDAC inhibition. BuA or MS-275 time- and
dose-dependently reduced mRNA expression (Fig. 2 a) and
protein levels (17 
 
 
 
 3% of control; Fig. 2 b) of 
 
HoxA9
 
.
Moreover, the down-regulation of 
 
HDAC1
 
 by small inter-
fering RNA (siRNA) reduced 
 
HoxA9
 
 expression (Fig. 2 c).
In contrast, the homeodomain transcription factor HoxD9
was not regulated (Fig. 2 b) and HDAC inhibitors caused
only a minor reduction in mRNA levels of HoxB5 (77 
 
 
 
11%; Fig. 2 a), indicating that 
 
HoxA9
 
 is rather specifically
regulated by HDAC.
 
HoxA9
 
 is essential for postnatal neovascularization
 
Next, we determined the role of 
 
HoxA9
 
 in postnatal neovas-
cularization using a previously described hind limb ischemia
model and measured the recovery of limb blood flow in WT
versus heterozygote 
 
HoxA9
 
 
 
/
 
 
 
 and homozygote 
 
HoxA9
 
 
 
/
 
 
 
mice. As depicted in Fig. 3 a, 
 
HoxA9
 
 
 
/
 
 
 
 and 
 
HoxA9
 
 
 
/
 
 
Figure 2. HDAC inhibitors decrease expression levels of HoxA9 
transcription factor. (a) RT-PCR of HoxA9 (top) and HoxB5 (bottom) 
after exposure of peripheral blood MNCs to endothelial differentiation 
conditions for 72 h in the presence or absence of 2 mM BuA, 10  M 
MS-275, or 2.5  M TSA. GAPDH mRNA expression is shown as a control 
(co; n   3). (b) Western blot analysis of HoxA9, HoxD9, p21, histone H3 
di-acetylation at lysine residues K9 and K14 (Ac-H3), total histone H3, 
and tubulin from peripheral blood MNCs after incubating in endothelial 
medium in the presence or absence of 2 mM BuA or 10  M MS-275 
(n   3–6). (c) Western blot analysis after transfection with siRNA 
directed against HDAC1 compared with scrambled (scr) in the presence or 
absence of 1  M TSA (n   3).
Figure 3. Role of HoxA9 for postnatal neovascularization after 
ischemia. (a) Incidence of necrotic limbs in wild-type (WT) versus het-
erozygote HoxA9 /  and homozygote HoxA9 /  mice after hind limb 
ischemia by ligation of the femoral artery (n   6/group). (b) For morpho-
logical analysis, myocytes were identified by staining for laminin (green) 
in ischemic tissue of WT (left) and homozygote HoxA9 /  mice (right). 
(c) Conductant vessels were defined by size ( 20  m) and positive stain-
ing for  –smooth muscle actin (red). 
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mice showed a severely impaired recovery of blood flow as
evidenced by a significantly higher incidence of limb necro-
sis. Limb perfusion as assessed by laser Doppler 2 wk after the
induction of ischemia was significantly reduced in HoxA9   
as compared with WT mice (26.9   14.3% compared with
WT; P   0.05). Consistently, HoxA9 /  mice exhibited ex-
tensive thigh muscle necrosis and a reduced number of arte-
rioles (Fig. 3, b and c), demonstrating that HoxA9 is essential
for postnatal neovascularization and blood flow recovery af-
ter hind limb ischemia.
HoxA9 contributes to the endothelial commitment of 
progenitor cells
To test the hypothesis that HoxA9 is important for endothe-
lial commitment, we measured HoxA9 expression during
endothelial differentiation of peripheral blood–derived pro-
genitor cells. HoxA9 expression increased during differentia-
tion of peripheral blood–derived progenitors toward an en-
dothelial phenotype (Fig. 4 a). The increase in HoxA9
expression during endothelial differentiation and maturation
was paralleled by an enhanced expression of the endothelial
marker proteins eNOS and VEGF-R2 in peripheral blood–
derived progenitor cells (reference 30; unpublished data).
Additionally, we determined the expression of HoxA9 dur-
ing the endothelial differentiation of ES cells as a model of in
vitro endothelial differentiation. Similar to the finding in pe-
ripheral blood–derived adult EPCs, the endothelial differen-
tiation of ES cells was associated with an increased ex-
pression of HoxA9 that coincided with the increase in
endothelial marker genes such as eNOS and VEGF-R2 (Fig.
4, b and c). Thus, elevated HoxA9 gene expression is associ-
ated with an increased endothelial commitment, as deter-
mined by the expression of endothelial marker genes.
We transduced blood-derived MNCs with a HoxA9 ad-
enovirus to test whether modulation of HoxA9 expression is
capable of regulating the number of EPCs. HoxA9 overex-
pression increased the yield of EPCs significantly (Fig. 4 d).
Moreover, we determined the number of EPCs in homozy-
gote and heterozygote HoxA9-deficient mice. HoxA9 / 
and HoxA9 /  mice showed a significantly reduced number
of Dil-ac-LDL  adherent cells and outgrowing EPC colo-
nies (Fig. 4, e and f ).  These data indicate that HoxA9 plays a
critical role in the endothelial commitment of adult progeni-
tor cells.
HoxA9 regulates eNOS, VEGF-R2, and VE-cadherin 
gene expression
To further substantiate that HoxA9 plays a critical role in the
expression of endothelial genes, we determined whether
HoxA9 is required for the maintenance of endothelial
marker gene expression in human umbilical vein endothelial
cells (HUVECs) as a model for mature endothelial cells. The
inhibition of HoxA9 expression by siRNA reduced the
mRNA expression of the endothelial marker genes eNOS,
VEGF-R2, and VE-cadherin in mature endothelial cells (Fig.
5, a and b). Moreover, HoxA9 siRNA inhibited eNOS pro-
tein expression (Fig. 5 c) and the generation of nitric oxide,
as measured by DAF-2DA staining, from 46   6 arbitrary
units in scrambled oligonucleotide-treated to 11   3 arbi-
trary units in siRNA-treated endothelial cells (n   4, P  
0.001).  HoxA9-deficient mice consistently showed a re-
duced eNOS protein expression in the heart (Fig. 5 d). In
contrast, overexpression of HoxA9 enhanced the expression
of eNOS (Fig. 5 e). These data demonstrate that HoxA9 reg-
ulates the expression of endothelial marker genes in vitro and
in vivo.
To assess whether HoxA9 interacts with the eNOS,
VEGF-R2 and VE-cadherin promoters, we performed chro-
matin immunoprecipitation assays. After cross-linking, im-
munoprecipitates of endogenous HoxA9 were subjected to
PCR using primers directed against the eNOS, VEGF-R2,
and VE-cadherin promoters. Endogenous HoxA9 bound to
the eNOS and the VEGF-R2 promoters (Fig. 6 a), whereas
Figure 4. Expression of HoxA9 during differentiation of progenitor 
cells. (a) Western blot analysis of HoxA9 protein expression during ex vivo 
endothelial differentiation of peripheral blood–derived EPCs for the indicated 
days. Reprobe with extracellular signal–related kinase (ERK)1/2 indicates 
equal protein loading (n   3). (b) RT-PCR analysis of HoxA9, eNOS, VEGF-R2, 
and GAPDH mRNA expression in ES cells at baseline (day 0) and after ex-
posure toward endothelial differentiation conditions (day 7). (c) Western 
blot analysis of eNOS and VEGF-R2 protein expression in ES cells at baseline 
(day 0) and after exposure toward endothelial differentiation conditions 
(day 7). A representative reprobe with tubulin indicates equal protein 
loading. (d) Numbers of peripheral blood MNC–derived EPCs after trans-
fection with HoxA9 adenovirus (*, P   0.05 vs. lacZ control vector; n   10). 
Expression control is shown (right). (e and f) Cultivated spleen MNC-derived 
Dil-ac-LDL  cells (e) and outgrowing EPC colonies (f) from HoxA9 / , 
HoxA9 / , or WT mice (*, P   0.05 vs. WT, n   6).JEM VOL. 201, June 6, 2005 1829
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HoxA9 did not interact with the VE-cadherin promoter, at
least not within the specific region  1163 to  380 bp up-
stream of ATG investigated (Fig. 6 a). To test the specificity
of the binding of HoxA9 to the eNOS and VEGF-R2 pro-
moters, HUVECs were transiently transfected with WT
HoxA9 or a HoxA9 mutant (mt) lacking the DNA-binding
domain ( 206-272 [reference 27]; Fig. 6 b). Overexpressed
WT HoxA9 bound to the eNOS and VEGF-R2 promoters,
whereas the HoxA9 mt showed no binding (Fig. 6 c), con-
firming the specificity of the interaction. To determine the
promoter activation by HoxA9, we used reporter gene con-
structs driven by the eNOS, VEGF-R2, or VE-cadherin
promoters. HoxA9 significantly increased eNOS, VEGF-R2,
and VE-cadherin promoter activation (Fig. 6, d–f ).  Thus,
HoxA9 regulates the transcription of prototypic endothelial
marker genes in endothelial cells.
Physiological levels of shear stress induce endothelial 
maturation of progenitor cells in a HoxA9-dependent manner
EPCs not only home to sites of ischemia, but also to denuded
arteries, thereby promoting the recovery of the endothelial
monolayer after a denuding injury. Immediately after attach-
ment, progenitor cells are exposed to laminar blood flow
(31–33). Because laminar blood flow increases the expression
of various endothelial genes such as eNOS (for review see
reference 34) and VEGF-R2 (35, 36), we hypothesized that
shear stress may enhance the endothelial maturation of pro-
genitor cells by the up-regulation of HoxA9. Indeed, shear
stress stimulated the expression of HoxA9 in a time- and
dose-dependent manner (Fig. 7 a). Moreover, the exposure
of peripheral blood MNC–derived EPCs to shear stress in-
creased the expression of VEGF-R2 (Fig. 7 b), eNOS, and
the expression of a VEGF-R2 promoter–driven reporter gene
(unpublished data). Shear stress also enhanced VEGF-R2 ex-
pression in isolated CD34  hematopoietic progenitor cells
Figure 5. Essential role of HoxA9 for endothelial lineage marker 
expression in mature endothelial cells. (a) RT-PCR analysis of mRNA 
expression of the indicated markers in HUVECs transfected with scrambled 
siRNA or siRNA against HoxA9. A representative agarose gel is shown. 
(b) Quantitative RT-PCR (Light cycler) of the indicated markers in HUVECs 
transfected with scrambled siRNA or siRNA against HoxA9 (n   4). 
(c) eNOS and HoxA9 protein expression after transfection of HUVECs with 
scrambled siRNA or siRNA against HoxA9 (*, P   0.05 vs. scrambled, n   4). 
(d) eNOS protein expression in hearts of WT, HoxA9 / , and HoxA9 /  mice 
(top, representative blot; bottom, quantification; n   4/group;*, P   0.05 
vs. WT). (e) eNOS protein expression after transient transfection of a plasmid 
encoding HoxA9 in HUVECs (*, P   0.05). (right) Representative Western 
blot analysis with tubulin as a loading control and staining against c-myc 
to indicate overexpression of the tagged HoxA9 insert.
Figure 6. HoxA9 directly binds to the promoter of eNOS and 
VEGF-R2. (a) Chromatin immunoprecipitation (ChIP) of endogenous HoxA9 
followed by PCR directed against the promoter regions of VEGF-R2, VE-
cadherin, eNOS, and, as a positive control, EphB4 (n   3). Genomic DNA 
(gDNA) was used as positive control for PCR. (b) Western blot analysis of 
immunoprecipitated HoxA9 WT or HoxA9 mt in transfected HUVECs. (c) ChIP 
of DNA-bound myc-tagged HoxA9 from HUVEC lysates after the transient 
transfection of HoxA9 WT or of a truncated HoxA9 construct deficient 
in the DNA-binding domain (HoxA9 mt) followed by PCR analysis with 
promoter-specific primers against sequences of the eNOS promoter (top) or 
VEGF-R2 promoter (bottom; n   3). (d–f) Transcriptional activation of the 
luciferase reporter gene under the regulatory control of the eNOS (d), 
VEGF-R2 (e), or VE-cadherin promoter (f) in HoxA9 WT or HoxA9 mt cotrans-
fected HUVEC (*, P   0.05; n   3–6 vs. mock; RLU, relative light units).HOXA9 REGULATES ENDOTHELIAL COMMITMENT | Rössig et al. 1830
(Fig. 7 b). Concomitantly, the expression of the pan-leuko-
cyte marker protein CD45 decreased (unpublished data),
which was consistent with a maturation toward the endothe-
lial lineage. In contrast, when macrophages were exposed to
shear stress, no increase in VEGF-R2 expression was noted
(Fig. 7 b), indicating that the capacity of shear stress to induce
endothelial lineage marker expression is restricted to progeni-
tor cells and mature endothelial cells. Next, we determined
whether the shear stress–induced expression of endothelial-
committed genes is indeed mediated via HoxA9. A blockade
of HoxA9 gene expression by siRNA abrogated the shear
stress–stimulated increase in eNOS and VEGF-R2 expression
(Fig. 7 c), documenting that shear stress requires HoxA9 to
up-regulate endothelial marker genes.
HoxA9 overexpression partially rescues the HDAC inhibitor–
mediated blockade of endothelial differentiation
To finally determine whether the HDAC inhibitor–mediated
down-regulation of HoxA9 is indeed causally involved in the
reduction of endothelial commitment and down-regulation
of endothelial marker genes by HDAC inhibitor treatment,
we overexpressed HoxA9 by adenoviral transduction. Indeed,
HoxA9 overexpression partially reversed the down-regulation
of the number of EPCs by HDAC inhibition (Fig. 8 a). To
determine whether the HDAC inhibitor–induced down-reg-
ulation of eNOS (18) is mediated by transcriptional repres-
sion of HoxA9, we overexpressed HoxA9 before treatment of
the cells with HDAC inhibitors. Indeed, the profound
down-regulation of eNOS protein expression by HDAC in-
hibitors was prevented by overexpression of HoxA9 (Fig. 8 b)
suggesting that the transcriptional repression of HoxA9 by
HDAC inhibitors may contribute to eNOS down-regulation
and inhibition of endothelial commitment.
DISCUSSION
This study demonstrates that the endothelial lineage commit-
ment of circulating blood- or bone marrow–derived progen-
itor cells requires HDAC activity. The inhibition of HDACs
decreased the expression of the transcription factor HoxA9
and reduced the number of endothelial cells derived from dif-
ferent progenitor cell sources. HoxA9 regulates various typi-
cal endothelial marker proteins, which are also important for
Figure 7. Shear stress induction of HoxA9, eNOS, and VEGF-R2 is 
sensitive to HDAC inhibition. (a) Dose- and time-dependent regulation of 
HoxA9 expression (Western blot) after exposure of endothelial cells to shear 
stress. (left) Representative dose-dependency; (right) quantification of time-
dependency (15 dynes/cm2; n   3–6 experiments). (b) FACS analysis of 
VEGF-R2 expression in peripheral blood–derived EPCs (left), human CD34  
cells (middle), and macrophages (right) after exposure of the respective cell 
type to shear stress (15 dynes/cm2 for 24 h). (top) Representative traces; 
(bottom) quantitative analysis. (c) Shear stress (15 dynes/cm2 for 24 h)–
stimulated expression of eNOS and VEGF-R2 after HoxA9 siRNA transfection 
compared with scrambled oligonucleotides. (left) Representative RT-PCR; 
right, quantification of n   3 (*, P   0.05 vs. scrambled   shear stress).JEM VOL. 201, June 6, 2005 1831
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the functional activity of endothelial cells. HoxA9 deficiency
reduces endothelial lineage commitment and results in severe
impairment of neovascularization, demonstrating an impor-
tant role of HoxA9 in postnatal neovascularization.
HDACs comprise at least 17 genes, of which HDAC1,
HDAC3, and SIRT1 are expressed in human peripheral
blood–derived EPCs (unpublished data). The pharmacologi-
cal inhibition of class I and II HDACs by structurally differ-
ent pharmacological HDAC inhibitors abrogated HoxA9 ex-
pression and the endothelial commitment of progenitor cells.
Furthermore, a specific down-regulation of HDAC1 by
siRNA reduced the expression of HoxA9. In contrast,
HoxD9 and HoxB5 were not significantly regulated by
HDAC inhibitors, implicating a specific dependency of
HoxA9 transcription on HDAC activity. HDACs are a com-
ponent of the ALL-1 supercomplex, which binds to the
HoxA9 promoter and is required for HoxA9 transcription
(37). Thus, one may speculate that HDAC activity is neces-
sary for the ALL-1 supercomplex to allow for transcription
of HoxA9 (37).
Our data demonstrate that HoxA9 is required for postna-
tal neovascularization after ischemia. Previous studies addi-
tionally documented that the inhibition of HDAC blocks
tumor angiogenesis (17). However, the importance of
HDAC and HoxA9 for the embryonic development of vas-
cular structures in vivo is unclear. In fact, several lines of ev-
idence indicate that HDAC1 and HoxA9 are not essential
for embryonic vessel formation. In contrast to VEGF gene
deficiency, which is lethal because of impaired vessel forma-
tion even at the level of haploinsufficiency (38), or VEGF-
R2 knockout mice, which die between embryonic days 8.5
and 9.5 from the lack of any vascular formation (39), no ab-
normalities with respect to embryonic vascularization were
obvious in HDAC1 /  or HoxA9 /  mice (40, 41). In our
experiments, however, HDAC inhibitors abrogated embry-
onic angiogenesis and vasculogenesis in the allantois ex vivo
assay. This discrepancy might well be rationalized by the
broad spectrum inhibitory effect of the pharmacological
HDAC inhibitors used in the present study and may indicate
that the specific lack of HDAC1 might be compensated for
by the various other members of the HDAC family in vivo.
Likewise, the lack of a severe embryonic phenotype of
HoxA9 /  mice might also be caused by compensation by
other members of the Hox family such as HoxB5 during
embryonic development in vivo (23). However, our data
clearly indicate that HoxA9 is required for adult vasculogen-
esis. Indeed, HoxA9 /  and HoxA9 /  mice showed a se-
vere impairment of endothelial colony formation, blood
flow recovery, and functional regeneration after the induc-
tion of ischemia. Thus, one may speculate that mechanisms
regulating postnatal neovascularization are not necessarily
identical to the mechanisms operational during embryonic
vascular development.
Why is HoxA9 important for postnatal neovasculariza-
tion? In addition to the requirement of HoxA9 for endothe-
lial progenitor colony formation and adult vasculogenesis, our
data indicate that HoxA9 directly regulates a variety of key
endothelial genes that are involved in the functional matura-
tion and activity of endothelial cells. All three HoxA9 target
genes, eNOS (42, 43), VEGF-R2 (39), and VE-cadherin
(44), are crucial for angiogenesis. Moreover, the reduction of
HoxA9 additionally results in the reduced expression of
EphB4 and, thus, inhibits endothelial migration in vitro (27).
The reduction of these HoxA9 regulated genes in vivo (as
shown for the eNOS) may contribute to the severe neovas-
cularization defect of HoxA9-deficient mice. In addition,
HoxA9 regulates myeloid and lymphoid hematopoiesis (25)
and, therefore, may affect inflammation-mediated angiogene-
sis. However, a reduction of myeloid cells was detected in
homozygote, but not in heterozygote, mice (25), whereas in
our study heterozygote mice showed a severe impairment of
neovascularization and endothelial colony forming activity.
Furthermore, the overall peripheral white blood cell counts
after the induction of ischemia were not notably different be-
tween HoxA9-deficient mice and WT littermates (unpub-
lished data). Thus, the impaired neovascularization capacity
of HoxA9 /  and HoxA9 /  mice is most likely not related
to a general imbalance of inflammatory cells.
Figure 8. Rescue of HDAC inhibitor–mediated reduction of endo-
thelial progenitors and eNOS expression by HoxA9 overexpression. 
(a) Numbers of peripheral blood MNC–derived EPCs after transfection with 
HoxA9 adenovirus in the presence or absence of 0.5 mM BuA (*, P   0.05 
vs. lacZ control vector; n   4). (b) eNOS expression (Western blot analysis) 
in HUVEC transfected with HoxA9 WT or pcDNA3.1 control plasmid (mock) 
after incubation with 2  M TSA for 24 h. (top) Quantification; (bottom) 
representative Western blot analysis (n   11; *, P   0.05 vs. mock-
transfected cells; #, P   0.05 vs. mock   TSA).HOXA9 REGULATES ENDOTHELIAL COMMITMENT | Rössig et al. 1832
Finally, our data provide novel insights into the proto-
typic physiological mechanism inducing the maturation of
endothelial cells. Shear stress is not only one of the most
powerful antiatherosclerotic factors, but is also an absolute
prerequisite for a functionally intact endothelial monolayer.
We demonstrate that the up-regulation of the endothelial
signature gene pattern is dependent on HoxA9. Not only did
shear stress increase the expression of endothelial marker
proteins such as eNOS and VEGF-R2, but it also concomi-
tantly down-regulated the pan-leukocyte marker CD45,
which is expressed on hematopoietic progenitor cells. These
data clearly indicate that shear stress is capable of promoting
the commitment of progenitor cells to an endothelial pheno-
type. The stimulation of HoxA9 expression and subsequent
endothelial maturation by shear stress may considerably con-
tribute to a timely recovery of the endothelial monolayer af-
ter injury to prevent atherosclerotic lesion development and
restenosis formation, respectively (32, 33, 45, 46).
This study demonstrates that the HDAC-dependent
transcription of HoxA9 is necessary for ex vivo maturation of
progenitor cells toward the endothelial lineage. These find-
ings not only contribute to a better understanding of postna-
tal endothelial maturation, but, given the pivotal role of
EPCs for neovascularization of ischemic tissue and reendo-
thelialization, may also provide important therapeutic targets.
Of note, the inhibition of adult vasculogenesis by HDAC
inhibitors may also contribute to the reported profound anti-
tumor activity of HDAC inhibitors (15).
MATERIALS AND METHODS
Isolation and ex vivo endothelial differentiation of EPCs. Ex vivo
EPC differentiation from circulating MNCs was assayed as described previ-
ously (28). In brief, MNCs were isolated by density gradient centrifugation
with Biocoll separating solution (density 1.077; Biochrom AG) from human
peripheral blood buffy coats. Immediately after isolation, 8   106 MNC/ml
of medium was plated on culture dishes coated with human fibronectin and
maintained in endothelial basal medium (EBM; Cambrex) supplemented
with EGM SingleQuots (Cambrex) and 20% FCS (GIBCO BRL). After 3 d
in culture, nonadherent cells were removed by thorough washing with PBS.
Adherent cells were stained with 2.4  g/ml Dil-Ac-LDL (Harbor Bio-Prod-
ucts) at 37 C for 1 h and fixed with 4% paraformaldehyde for 10 min. Puri-
fied human CD34  BM MNCs (BMCs) were purchased from Cambrex and
were differentiated to EPCs under the same conditions as described above.
For the preparation of Sca-1 /lin  BMC-derived EPCs, murine BM
was isolated from the hindlimbs of 6–8-wk-old female C57BL/6 mice.
Then, cells were filtrated using a 40- m pore size cell strainer. After block-
ing with purified anti–mouse CD16/CD32 (Fc III/II receptor) antibodies
(1:100; BD Biosciences), washed cells were incubated with a biotinylated
anti–lineage marker antibody cocktail (Becton Dickinson) and antibiotin
microbeads (Miltenyi Biotec), and isolated with an automated magnetic cell
sorting device (autoMACS; Miltenyi Biotec). Separated lin  BMCs were
incubated with microbeads directly conjugated to anti–Sca-1 antibodies,
and Sca-1 /lin  BMCs were isolated by a second run through the au-
toMACS. To assess the capacities of these immature BM stem cells, 0.5–
1.0   106 pooled Sca-1 /lin  BMCs were plated on 24-well culture dishes
coated with human fibronectin and maintained in EBM supplemented with
EGM SingleQuots and 20% FCS. After 3 d in culture, adherent Sca-1 /
lin  BMCs were stained with Dil-Ac-LDL and were fixed. Then, cells
were stained for vWF (Acris Antibodies) and the nuclear marker TO-
PRO-3 iodide (Molecular Probes), or against 10  g/ml lectin by incubat-
ing with FITC-labeled Ulex europaeus agglutinin I (Sigma-Aldrich) for 1 h.
Staining for both vWF or lectin, and Dil-Ac-LDL, was evaluated by confo-
cal microscopy.
For the isolation of spleen-derived EPCs, murine MNCs were isolated
from homogenized splenic tissue derived from HoxA9 /  (provided by H.
Jeffrey Lawrence, University of California, San Francisco, Veteran’s Admin-
istration Medical Center, San Francisco, CA) or WT littermates by density
gradient centrifugation with Biocoll separating solution. 4   106 MNCs
were plated on fibronectin-coated 24-well plates in 0.5 ml EBM supple-
mented with EGM SingleQuots and 20% FCS and were stained as de-
scribed above. Outgrowing colonies were detected after 10 d.
Cell culture. Pooled HUVECs were purchased from CellSystems and
cultured as previously described (27). HUVECs were exposed to laminar
flow in a cone-and-plate apparatus as previously described (47). For shear
stress experiments, human CD34  hematopoietic progenitor cells were pu-
rified from MNCs by positive selection with anti-CD34 microbeads (Mil-
tenyi Biotec; reference 28). For the cultivation of macrophages, CD14 
monocytes were purified from MNCs by positive selection with anti-CD14
microbeads (Miltenyi Biotec) using a magnetic cell sorter (Miltenyi Biotec).
Purity assessed by FACS analysis was  95%. CD14  monocytes were incu-
bated in RPMI 1640 with 10% FCS in the presence of 50 ng/ml M-CSF to
induce macrophage differentiation (29).
Allantois assay. Allantoides were isolated as previously described (48). In
brief, embryos at 8.5 d postcoitum were dissected in PBS at 4 C, and the al-
lantoides were excised and seeded into four-chambered culture slides (Nal-
gene Nunc International) containing 0.4 ml DMEM with 10% FCS, 2
mmol/liter L-glutamine, 100 U/ml penicillin, and 100  g/ml streptomycin
(all reagents obtained from Life Technologies). Explants were cultured at
37 C in a 5% CO2 incubator for 18–20 h in the presence or absence of the
HDAC inhibitors. The allantois cultures were fixed for 20 min at 25 C
with 4% paraformaldehyde, washed twice in PBS, permeabilized for 15 min
at 25 C with 0.02% Triton X-100 in PBS, blocked for 1 h at 25 C with 3%
BSA (Sigma-Aldrich) in PBS, and stained with PECAM-1 antibody
(MEC13.3; reference 49).
Western blot analysis. Cells were lysed with buffer (20 mmol/liter Tris,
pH 7.4, 150 mmol/liter NaCl, 1 mmol/liter EDTA, 1 mmol/liter EGTA, 1%
Triton X-100, 2.5 mmol/liter sodium pyrophosphate, 1 mmol/liter  -glycero-
phosphate, 1 mmol/liter Na3VO4, 1  g/ml leupeptin, 1 mmol/liter PMSF) for
15 min on ice. After centrifuging at 20,000 g for 15 min at 4 C, protein content
was measured according to the Bradford method. Homogenates (40  g per
lane) were separated on SDS-polyacrylamide gels and transferred to polyvi-
nylidene difluoride membranes, which were then incubated with antibodies to
p21 (BD Biosciences), HDAC1 (Abcam), HoxA9, and HoxD9 (Santa Cruz
Biotechnology, Inc.), K9-K14-diacetylated histone H3 (Upstate Biotechnol-
ogy), total histone H3 (Cell Signaling), extracellular signal–related kinase 1/2
(Cell Signaling), eNOS (BD Biosciences), or tubulin (NeoMarkers).
RT-PCR. Total RNA was isolated and either subjected to conventional
RT-PCR or quantitative RT-PCR using the oligonucleotide primers sum-
marized in Tables S1 and S2 (available at http://www.jem.org/cgi/content/
full/jem.20042097/DC1). Quantification of mRNA was performed in a
one-step RT-PCR reaction using the LightCycler (Roche Diagnostics) real-
time thermocycler according to the manufacturer’s instructions. Amplifica-
tion was performed with 40 cycles at an annealing temperature of 61 C.
Copy numbers were calculated by the instrument software (Roche Diagnos-
tics) from standard curves of an in vitro–transcribed IL-10 cytokine primer
mix (Light Cycler control kit RNA; Roche Diagnostics). The specificity of
the amplification reaction was determined by a melting curve analysis.
Generation of recombinant adenovirus and adenoviral infection.
HoxA9 (transcript variant 1) was amplified by RT-PCR and cloned into a
shuttle pAd Track-CMV vector. This plasmid was linearized by digestingJEM VOL. 201, June 6, 2005 1833
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with restriction endonuclease PmeI and subsequently cotransformed into
Escherichia coli BJ5183 cells with an adenoviral backbone pAdEasy-1 plasmid
(all plasmids and E. coli cells were a gift from B. Vogelstein, Howard
Hughes Medical Institute, Johns Hopkins Medical Institutions, Baltimore,
MD). Recombinants were selected by kanamycin resistance. Finally, re-
combinants were transfected into HEK293 cells. Recombinant adenovi-
ruses were generated within 7–10 d. The lacZ gene codes for the enzyme
 -galactosidase. The lacZ adenovirus was used as control.
Peripheral blood MNCs (4   106 cells/1-cm well) were resuspended
in 2.5 ml RPMI 1640 (GIBCO BRL) with 10% FCS and preincubated for
30 min with a mixture of adenovirus, 10  l Antennapedia peptide (RQIKI-
WFQNRRMKWKK; 2.5 mM; Biosyntan), and 100  l Optimem (Life
Technologies). After 24 h, 4   106 cells were resuspended in 1 ml EBM
supplemented with EGM SingleQuots and 20% FCS and plated on fi-
bronectin-coated wells.
Endothelial differentiation of ES cells. CJ7 ES cells, a 129/Sv-derived
cell line, were cultivated as previously described (50). To initiate ES cell dif-
ferentiation and embryonic body formation, ES cells were trypsinized and
suspended in IMDM (Life Technologies) with 15% FBS, 10  g/ml insulin
(Sigma-Aldrich), 100 U/ml penicillin, 100  g/ml streptomycin, 450  mol/
liter monothioglycerol, and endothelial differentiation promoting growth
factors including 50 ng/ml recombinant human VEGF (PeproTech), 2
U/ml recombinant human erythropoietin (Cilag AG), 100 ng/ml human
basic fibroblast growth factor (Genzyme), and 10 ng/ml murine interleukin
6 (Genzyme). After 7 d, ES cell–derived endothelial cells were collected by
anti-CD31 immunomagnetic selection (51).
Reporter gene assay. Reporter gene constructs were previously described
(1.6-kb human eNOS promoter fragment [reference 52]; 4-kb human
VEGF-R2 promoter [reference 36]). The VE-cadherin promoter (3,032-kb
fragment:   2928/ 104) was cloned into KpnI–XhoI restriction sites in
pGl3 enhancer plasmid (Promega). 3.5   105 HUVECs were transiently
transfected with 3  g plasmid DNA using 18  l Superfect (QIAGEN) as
previously described (47). After incubation, cells were lysed with lysis buffer
(Promega), and luciferase activity was measured using the Luciferase System
(Promega) with a luminometer (model Luminat LB 9501; Berthold).
Murine ischemic hind limb model. The effect of HoxA9 on ischemia-
induced neovascularization was investigated in a murine model of hind limb is-
chemia. The present study was performed with the permission of the State of
Hesse (Regierungspräsidium Darmstadt), according to section 8 of the German
Law for the Protection of Animals, and conforms to the Guide for the Care and
Use of Laboratory Animals measurements. In brief, the proximal portion of the
femoral artery, including the superficial and the deep branch, as well as the dis-
tal portion of the saphenous artery, was ligated and all arterial branches between
the ligations were obliterated using an electrical coagulator. The overlying skin
was closed using three surgical staples. 2 wk later, we determined the morphol-
ogy of the limb and measured the ischemic (right) to normal (left) limb blood
flow ratio using a laser Doppler blood flow meter (model moorLDI-Mark 2;
Moor Instruments). Before initiating scanning, mice were placed on a heating
pad at 37 C to minimize variations in temperature. After the recording of com-
plete scan laser Doppler color images, the perfusion of the ischemic and nonis-
chemic limb was calculated on the basis of colored histogram pixels. To mini-
mize variables, including ambient light and temperature, calculated perfusion
was expressed as the ratio of ischemic to nonischemic hind limb perfusion.
For morphological analysis, 8- m frozen sections of the adductor and
semimembranous muscles were used. Myocyte membranes were stained us-
ing an antibody to laminin (rabbit) followed by anti–rabbit-Alexa 488.
Conductance vessels in the adductor and semimembranous muscles were
identified by size ( 20  m) and staining using a Cy3 labeled mouse mono-
clonal antibody for smooth muscle actin (Sigma-Aldrich).
Statistics. Data are expressed as mean   SEM or as indicated in the figure
legends. Two treatment groups were compared with the independent sam-
ples t test, and three or more groups by one-way analysis of variance fol-
lowed by post-hoc analysis adjusted with a least significant difference cor-
rection for multiple comparisons (SPSS Inc.). Results were considered
statistically significant when P   0.05.
Online supplemental material. Fig. S1 shows a representative flow cy-
tometric characterization of endothelial marker expression in adherent hu-
man peripheral blood MNC–derived EPCs. Fig. S2 presents a comparison
of the effect of structural analoga without HDAC inhibitory capacity (2
mM acetate and 1 mM valpromide) and with HDAC inhibitory capacity (2
mM BuA and 1 mM valproate) on the ex vivo formation of EPCs from hu-
man peripheral blood MNCs during 72 h of incubation under endothelial
differentiation conditions. Fig. S3 shows cell matrix adhesion. Fig. S4 pre-
sents the effect of a 72-h incubation of peripheral blood MNCs with 2 mM
BuA, 10  M MS-275, or 1 mM valproate (VPA) under endothelial differ-
entiation conditions on apoptosis. Table S1 summarizes the sequences of
the oligonucleotide primer pairs (forward and reverse) used for RT-PCR.
Table S2 summarizes the sequences of the oligonucleotide primer pairs (for-
ward and reverse) used for quantitative RT-PCR (Light Cycler). Online
supplemental material is available at http://www.jem.org/cgi/content/full/
jem.20042097/DC1 or from the authors by request.
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